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Abstract
Patients with metabolic syndrome are at high-risk for development of atherosclerosis and cardiovascular events. The objective of 
this study was to examine the major determinants of coronary disease severity, including those coronary risk factors associated 
with metabolic syndrome, during the early period after an acute coronary episode. We tested the hypothesis that inflammatory 
markers, especially highly sensitive C-reactive protein (hsCRP), are related to coronary atherosclerosis, in addition to traditional 
coronary risk factors. Subjects of both genders aged 30 to 75 years (N = 116) were prospectively included if they had suffered 
a recent acute coronary syndrome (acute myocardial infarction or unstable angina pectoris requiring hospitalization) and if 
they had metabolic syndrome diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III. 
Patients were submitted to a coronary angiography and the burden of atherosclerosis was estimated by the Gensini score. The 
severity of coronary disease was correlated (Spearman’s or Pearson’s coefficient) with gender (r = 0.291, P = 0.008), age (r = 
0.218, P = 0.048), hsCRP (r = 0.256, P = 0.020), ApoB/ApoA ratio (r = 0.233, P = 0.041), and carotid intima-media thickness (r 
= 0.236, P = 0.041). After multiple linear regression, only male gender (P = 0.046) and hsCRP (P = 0.012) remained indepen-
dently associated with the Gensini score. In this high-risk population, male gender and high levels of hsCRP, two variables that 
can be easily obtained, were associated with more extensive coronary disease, identifying patients with the highest potential 
of developing new coronary events.
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Subjects with metabolic syndrome (MetS) are con-
sidered to be at high risk for coronary and cardiovascular 
events due to the clustering of cardiovascular risk factors, 
including central obesity, glucometabolic abnormalities, 
dyslipidemia, and increased blood pressure levels (1,2). In 
addition, MetS at hospital admission for an acute coronary 
syndrome (ACS) episode was identified as a strong and 
independent early predictor of mortality and morbidity in 
patients with non-clinically diagnosed diabetes (3). On the 
other hand, traditional coronary risk algorithms such as the 
Framingham risk score do not include triglycerides, obesity, 
or impaired fasting glycemia as variables for coronary risk 
stratification (4). 
Among novel risk markers, elevated highly sensitive 
C-reactive protein (hsCRP) levels were related to the 
MetS, and both hsCRP and MetS were independent pre-
dictors of new cardiovascular events (5). Indeed, several 
cohort studies have shown that hsCRP evaluation adds 
prognostic information to the cardiovascular risk predicted 
by the Framingham risk score, as well as for subjects with 
MetS, especially those with concomitant subclinical carotid 
atherosclerosis (6). 
Recently, the JUPITER trial (7), a primary prevention 
study for coronary artery disease, tested the predictive value 
of high hsCRP levels for the first occurrence of the major 
cardiovascular events in a very large population with rela-
tively low LDL-C levels. An impressive relationship between 
myocardial infarction, stroke and thromboembolic events 
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was observed with hsCRP, even in the absence of other 
traditional risk factors (7-9). Interestingly, in the JUPITER 
trial, over one third of the entire population consisted of 
patients with MetS (10). Previous studies have reported a 
different impact of metabolic syndrome according to gen-
der (11-13) on the relative risk for cardiovascular disease, 
possibly related to differences in the components of the 
MetS and other concomitant risk factors. Concerning the 
severity of coronary disease, a recent study showed a posi-
tive association between the number of components of the 
metabolic syndrome and the Gensini score (14). 
On the basis of these considerations, we determined 
the role of traditional and non-traditional risk factors, includ-
ing hsCRP, parameters of hemostasis and glucometabolic 
abnormalities, on the severity of coronary artery disease in 
subjects with MetS after an ACS episode. 
Patients and Methods
Patients
The study was conducted at São Paulo Hospital, Federal 
University of São Paulo, and was approved by the local 
Ethics Committee. Written informed consent was obtained 
from all patients.
Subjects of both genders aged 30 to 75 years (N = 116) 
were prospectively included if they had suffered a recent 
ACS event (acute myocardial infarction or unstable angina 
pectoris requiring hospitalization) and if they had MetS 
diagnosed according to the National Cholesterol Educa-
tion Program/Adult Treatment Panel (NCEP/ATP III) (4), 
which includes three or more of the following criteria: waist 
circumference >102 cm for men and >88 cm for women; 
blood pressure ≥130/85 mmHg or use of antihypertensive 
medication; plasma triglycerides ≥150 mg/dL; HDL-C <40 
mg/dL for men and <50 mg/dL for women; fasting glucose 
≥110 mg/dL or known diabetes. None of these patients 
were under treatment with hypolipidemic agents within 
the last 4 weeks. 
Laboratory tests 
Fasting blood samples were obtained 1-3 days after 
hospital discharge for measurement of cholesterol and 
triglycerides using an automated enzymatic kit (Opera 
Bayer, Germany), and LDL-C was estimated with the 
Friedewald formula (15). ApoB, ApoA1, Lp(a) (Array 360 
Beckmann, Germany), and hsCRP were measured by 
nephelometry (R100 Analyzer, Behringer, Germany). 
Plasma peroxidation was evaluated by the thiobarbituric 
acid reactive substance (TBARS) assay, which measures 
aldehyde formation. Fibrinogen, D-dimer, and factor VII 
were estimated by automated methods. Von Willebrand 
factor (vWF), and plasminogen-activator inhibitor-1 (PAI-1) 
were determined by enzyme-linked immunosorbent assay 
(ELISA). The homeostasis model for the assessment of 
insulin resistance (HOMA-IR) was calculated as insulin 
(mU/L) x (glucose [mg/dL] x 0.055) / 22.5 (16). The insu-
linogenic index was calculated as the difference between 
the plasma insulin values obtained at 30 and 0 min of the 
oral glucose tolerance test (OGTT) divided by the differ-
ence between the corresponding plasma glucose values 
(∆I30/∆G30). Adiponectin was measured by ELISA using a 
commercial kit (Human Adiponectin/Acrp30 Immunoassay - 
Quantiquine, R&D Systems). Glycated hemoglobin (HbA1C) 
was measured by high performance liquid chromatography. 
Body mass index (BMI) and waist circumference were re-
corded, and seated blood pressure was determined in both 
arms after a 5-min rest.
Coronary artery disease, intima media thickness, and 
flow-mediated dilation 
The severity of coronary atherosclerosis was examined 
by the Gensini score, which depends on the degree of lu-
minal narrowing and the importance of the site of coronary 
stenosis (17). According to the score, the narrowing of the 
lumen of the coronary arteries is graded as follows: 1 point, 
≤25%; 2 points, 26-50%; 4 points, 51-75%; 8 points, 76-
90%; 16 points, 91-99%, and 32 points for total occlusion. 
In addition, this primary score is multiplied by a factor that 
takes into account the importance of the coronary artery 
containing the lesion (5 for the left main coronary artery, 
2.5 for the proximal portion of the left anterior descending 
artery or proximal left circumflex artery and 1.5 for the mid-
region, 1 for the distal left anterior descending artery, and 
1 for the mid-distal region of the left circumflex artery or 
right coronary artery). The sum of the total score obtained 
was used for statistical analysis. 
The intima media thickness (IMT) of the carotid arteries 
was measured by ultrasonography with the patient in the 
supine position. High-resolution B-mode ultrasound images 
were scanned (Hewlett-Packard SONOS 5500, USA) with a 
linear transducer at frequencies >7.5 MHz. Measurements 
were made in both the left and right common carotid arteries. 
IMT was assessed in the artery segment within 1 cm of the 
bifurcation (18). The scans were recorded on S-VHS tape 
and analyzed offline by an image analyst who was unaware 
of subject characteristics. The maximal IMT of both carotid 
arteries was used for statistical analysis. The intra- and 
inter-sonographer variability was 0.05 ± 0.02 and 0.07 ± 
0.04 mm for the IMT measurements, respectively. 
Endothelial function was estimated by brachial flow-
mediated dilation (FMD) (19) measured in the morning 
after an overnight fast. After a 10-15 min rest, the brachial 
artery in the right antecubital fossa was visualized using 
a linear transducer >7.5 MHz. Once the optimal image of 
the artery was achieved, the baseline vessel diameter was 
measured. Reactive hyperemia was induced by inflating 
the blood pressure cuff to 200 mmHg, or at least 50 mmHg 
above systolic blood pressure, on the distal forearm for 5 
min and then deflating the cuff. End-diastolic images were 
obtained at the time of onset of the QRS complex on the 
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ECG. These images were acquired at baseline and 1 min 
after cuff deflation. The percent change from the baseline 
diameter to the value detected during reactive hyperemia 
was calculated to determine FMD. The intra- and inter-
sonographer variability was <1 and <2%, respectively. 
Statistical analysis
Data are reported as means ± SEM, unless otherwise 
specified. Correlations of clinical and laboratory parameters 
with the Gensini score were initially determined using Pear-
son’s coefficient for variables with normal distribution; for 
non-parametric variables, we used Spearman’s correlation 
coefficient. Multivariate regression was performed consider-
ing the variables associated with the Gensini score. Differ-
ences between genders were compared by the unpaired 
t-test or the chi-square test. When necessary, variables 
were log-transformed. All tests were two-tailed, and the 
level of significance was set at P < 0.05. All analyses were 
performed using the SPSS 11.5 for Windows. 
Results
 
Similar mean values were obtained for men and women 
regarding age (56 ± 1 vs 57 ± 1 years, respectively), BMI 
(30.2 ± 0.5 vs 30.1 ± 0.8 kg/m2), and the prevalence of 
hypertension (89.2 vs 90.5%), diabetes mellitus (40.3 vs 
54.4%), or impaired glucose tolerance (31.9 vs 30.9%). 
None of these differences were significant. Myocardial 
infarction as the presentation of ACS was more common 
among male subjects (55.4 vs 33.3%; P = 0.022). 
Several glucometabolic parameters were observed, in-
cluding adiponectin, HbA1C, insulinogenic index, HOMA-IR, 
fasting glucose, and glucose levels 2 h after OGTT. Only the 
last parameter differed between the two groups, with female 
patients showing higher glucose levels (P = 0.026 vs male 
subjects), as shown in Table 1. Among the components of 
MetS, male patients had a higher waist circumference (107 
± 11 vs 101 ± 10 cm; P = 0.004), and lower HDL-C levels 
(36 ± 1 vs 47 ± 2 mg/dL; P = 0.0001) than female patients. 
In addition, a higher number of MetS components was 
observed among male subjects (P = 0.001 vs females). 
Male patients also presented a lower ApoA1 and a higher 
ApoB/ApoA1 ratio than female subjects (Table 1).
Higher serum PAI-1 levels were observed in males 
than in females (39 ± 3 vs 30 ± 3 ng/mL; P = 0.033), and 
significant differences were not observed between genders 
for fibrinogen (427 ± 16 vs 384 ± 20 mg/dL), factor VII 
(124 ± 15 vs 129 ± 12%), vWF (93 ± 4 vs 102 ± 6%), and 
D-dimer (1054 ± 117 vs 968 ± 151 ng/mL). TBARS levels 
Table 1. Major biochemical characteristics of the study population.
Parameters Males
(N = 74)
Females 
(N = 42)
Cholesterol (mg/dL) 189 ± 5 197 ± 6
LDL-C (mg/dL) 115 ± 4 119 ± 6
HDL-C (mg/dL) 36 ± 1 47 ± 2*
Triglycerides (mg/dL) 185 ± 9 165 ± 13
ApoA1 (mg/dL) 100 ± 2 119 ± 3*
ApoB (mg/dL) 117 ± 3 110 ± 4
ApoB/ApoA1 1.19 ± 0.04 0.95 ± 0.04*
Glucose 2 h (OGTT, mg/dL) 208 ± 12 258 ± 18*
HbA1C (%) 6.4 ± 0.2 6.8 ± 0.3
HOMA-IR 6.5 ± 0.4 7.6 ± 0.8
ΔI30/ΔG30 112 ± 12 104 ± 17
Adiponectin (µg/mL) 6.2 ± 0.6 6.5 ± 0.6
hsCRP (mg/L) 18.2 ± 2.3 12.0 ± 2.1*
Data are reported as means ± SEM. OGTT = oral glucose toler-
ance test; HOMA-IR = homeostasis model assessment of insu-
lin resistance; ΔI30/ΔG30 = insulinogenic index; hsCRP = highly 
sensitive C-reactive protein. *P < 0.05 compared to males (un-
paired t-test). 
Table 2. Correlations between the Gensini score and other vari-
ables.
Variables Correlation coefficient
Gensini score x gender# 0.291*
Gensini score x age 0.218*
Gensini score x hsCRP 0.256*
Gensini score x apoB/apoA1 0.233*
Gensini score x BMI -0.088
Gensini score x waist circumference 0.057
Gensini score x SBP 0.062
Gensini score x DBP -0.086
Gensini score x fasting glycemia 0.135
Gensini score x HOMA-IR -0.045
Gensini score x cholesterol 0.113
Gensini score x LDL-C 0.158
Gensini score x HDL-C -0.143
Gensini score x triglycerides -0.023
Gensini score x Lp(a) 0.013
Gensini score x TBARS -0.011
Gensini score x cIMT 0.236*
Gensini score x factor VII -0.002
Gensini score x vW factor 0.008
Gensini score x D-dimer 0.117
Gensini score x PAI-1 0.113
Gensini score x fibrinogen 0.213
hsCRP = highly sensitive C-reactive protein; BMI = body mass 
index; SBP = systolic blood pressure; DBP = diastolic blood pres-
sure; HOMA-IR = homeostasis model assessment of insulin re-
sistance; TBARS = thiobarbituric acid reactive substances; cIMT 
= carotid intima-media thickness; vW factor = von Willebrand fac-
tor; PAI-1= plasminogen-activator inhibitor-1. *P < 0.05, variables 
significantly correlated with the Gensini score according to Pear-
son’s or Spearman’s correlation tests, when appropriate. #Spear-
man’s correlation coefficient.
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were also comparable between groups (1.7 ± 0.1 vs 1.7 ± 
0.1 nmol/L), but hsCRP was higher in male subjects (18.2 
± 2.3 vs 12.0 ± 2.1 mg/L; P = 0.049). 
The severity of coronary disease estimated by the 
Gensini score was higher among male than female patients 
(29 ± 3 vs 16 ± 5 points; P = 0.023), and a trend to a lower 
brachial FMD was observed in male subjects (13 ± 1 vs 16 
± 2%; P = 0.098), while the maximal carotid IMT was similar 
in the two groups (0.94 ± 0.02 vs 0.92 ± 0.02 mm). 
Univariate analysis showed that, of all reported pa-
rameters, only five variables correlated with the Gensini 
score (Table 2). Multiple linear regression analysis was 
performed to identify those variables independently related 
to the Gensini score, and the final model included age, 
male gender, hsCRP, and carotid IMT. As shown in Table 
3, only hsCRP and male gender remained independently 
associated with the Gensini score.
Discussion
In subjects with MetS the likelihood of developing car-
diovascular disease is approximately twice that observed 
in those who do not present the syndrome, even after ad-
justment for established risk factors (20-22). On this basis, 
patients with MetS should constitute a high risk group for 
further events or complications. In this context, our study 
found hsCRP levels and male gender as independent vari-
ables related to the severity of coronary disease. 
Our initial hypothesis was based on the concept of the 
relationship between insulin resistance and MetS. Thus, we 
believed that the extent and clinical features of coronary 
artery disease should be related to glucometabolic, lipid 
and hemostasis abnormalities. However, we found that 
variables such as HDL-C, triglycerides, glucose, insulin, 
and HOMA-IR were not significantly related to the extent of 
coronary artery disease evaluated by the Gensini score. In 
the Multi-Ethnic Study of Atherosclerosis (MESA) (23), the 
association of insulin resistance and MetS with subclinical 
atherosclerosis was also examined, but these investigators 
did not detect a significant relationship between HOMA-IR 
and the amount of coronary artery calcium. Indeed, as stated 
above, we did not identify any parameter of hemostasis that 
correlated with the severity of atherosclerosis.
Sex-specific differences reported in the general popula-
tion regarding cardiovascular or coronary disease mortality 
are outstandingly modified in diabetic populations. In the 
San Antonio Heart Study (24), when diabetes occurred with 
MetS, women with both features had a 14-fold increased 
risk of coronary heart disease mortality, whereas men had 
only a 4-fold increased risk. Our study showed that, at least 
when the glucometabolic profiles were similar between 
genders, male subjects with MetS at the time of ACS had 
more advanced atherosclerosis than female patients. 
In addition, a diagnosis of type 2 diabetes or impaired 
glucose tolerance was made in approximately 80% of the 
entire population, with similar rates for men and women. A 
positive association between increasing number of ATP III 
MetS components and coronary risk was reported in the 
Atherosclerosis Risk in Communities study, with high blood 
pressure and low HDL-C having the strongest effect (5). 
We found similar values for blood pressure between the 
two groups, but lower HDL-C levels among male subjects, 
who also had a higher number of MetS components. Post 
hoc analysis of the Treating to New Targets (TNT) study 
(25) showed that, among inpatients with coronary heart 
disease, significantly more patients with MetS had a major 
cardiovascular event at a median follow-up of 4.9 years 
than patients without MetS. 
The association of MetS with early carotid atherosclero-
sis was examined in a large cohort of hypertensive patients 
(26). Baseline carotid IMT was slightly greater among 
patients with MetS than among patients without the condi-
tion. The impact of the MetS components on carotid IMT 
examined in another trial (27) showed gender-based differ-
ences in the mechanisms of MetS-induced atherosclerosis 
(central obesity for men only, triglycerides for women only, 
whereas systolic blood pressure was significantly associ-
ated with the baseline value and progression of IMT for 
both men and women). We obtained similar carotid IMT for 
the two genders in spite of significant gender differences 
in the severity of coronary disease. Recently, Kasai et al. 
(28) reported a mean Gensini score of 32.8 for males and 
Table 3. Multiple linear regression of Gensini score and selected variables.
Variable Unstandardized coefficients Standardized coefficients t P 95% confidence interval
B SEM Beta Lower bound Upper bound
Constant -52.833 24.025 - -2.199 0.031 -100.737 -4.928
Age 0.510 0.315 0.178 1.617 0.110 -0.119 1.138
Male* 11.447 5.635 0.220 2.032 0.046 0.212 22.682
cIMT 37.073 21.868 0.184 1.695 0.094 -6.532 80.677
hsCRP* 0.340 0.132 0.274 2.571 0.012 0.076 0.603
Dependent variable: Gensini score. SEM = standard error of the mean. cIMT = carotid intima-media thickness; hsCRP = highly sensi-
tive C-reactive protein. *Variables independently associated with the Gensini score.
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21.9 for females with MetS according to the NCEP ATP 
III definition among patients who had undergone elective 
first coronary angiography. A positive association was 
found between the extension of coronary artery disease 
and the number of MetS components, and gender-related 
differences were also reported. However, in the study cited 
above, differences in ages between genders (mean ± SD) 
were relatively small (63.9 ± 10.1 years for males and 67.6 
± 11.5 years for females) (28), contributing in part to these 
results. In fact, it is well known that cardiovascular events, 
as well as the progression of coronary atherosclerosis, 
usually occur earlier in men than in women as reported in 
a large and multiethnic cohort (29). 
The contribution of low-grade inflammation in the devel-
opment of plaques has been recognized in the pathophysi-
ology of atherosclerosis. In this context, hsCRP has been 
proposed as the most promising marker of cardiovascular 
events and the JUPITER trial (7-10), which included a 
considerable number of patients of both genders with MetS 
and high CRP levels, was prematurely ended due to the 
unequivocal benefit of statin treatment for these subjects. 
In our patients, after adjustment by regression analysis, 
male gender and hsCRP levels were the only significant 
variables associated with the extent of coronary artery 
disease. Surprisingly, in our study no single glucometabolic 
variable was associated with the extent of coronary disease. 
However, both hsCRP levels and altered glycemia seem 
to be predictors of in-hospital cardiovascular events (30), 
and we recently reported high rates of glucometabolic 
disturbances among patients with MetS after an acute 
coronary event (31). 
Limitations
This study was conducted few days after an ACS, a fact 
that might have contributed to lower lipid levels and blood 
pressure than in stable clinical conditions before the ACS. 
In addition, at this time, high fasting glucose levels could 
be related to stress-induced hyperglycemia. All of these 
variables are components of the MetS. However, this is a 
common clinical scenario and the data collected with these 
possible biases were still useful to identify those patients 
with more extensive coronary disease. 
The best criteria for MetS definition in ACS patients are 
still being debated. According to some investigators, a modi-
fied ATP definition for MetS included blood glucose levels 
>140 mg/dL (as occasional blood glucose at admission), BMI 
>28 kg/m2 (instead of abdominal circumference), and self-
report of preexisting hypertension (3). In the INTERHEART 
study (32), the authors also included self-reported history 
of hypertension due to the use of beta-blockers, nitrates, 
and angiotensin-converting enzyme inhibitors, all of them 
capable of affecting blood pressure levels during hospitaliza-
tion. However, according to a recent hypertension survey 
in Brazil (33), not all patients are aware of their disease, 
and therefore a self-reported history of hypertension can 
underestimate the diagnosis of hypertension. 
We did not evaluate ACS patients without MetS to de-
termine if the correlation of hsCRP levels with the severity 
of coronary disease can be extended to these patients. 
However, a recent study confirmed the correlation of this 
variable with the Gensini score (r = 0.42, P < 0.001) among 
patients with acute or previous myocardial infarction as well 
as with stable or unstable angina pectoris in addition to 
controls who undergo coronary angiography (34). 
To the best of our knowledge, no previous study has 
described the entire complex of gender-related differences 
in the components of MetS, together with traditional and 
non-traditional coronary risk markers, and the extent of 
atherosclerosis among patients with MetS after ACS. We 
demonstrated that during the early period after an acute 
coronary syndrome, among several biochemical and im-
aging tests, inexpensive parameters such as hsCRP and 
male gender best predict the severity of coronary artery 
disease.
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